Nanoform Finland will be initiating the first human trial of a drug candidate nanoformed using the company’s CESS technology in 2020.
Nanoform Finland has revealed, in an Oct. 20, 2020 press release, that it will be initiating the first human trial of a drug candidate nanoformed using the company’s Controlled Expansion of Supercritical Solutions (CESS) technology during the fourth quarter of 2020.
The innovative nanoparticle medicine enabling company has reported that dosing will commence before the end of 2020 and results are expected to be available before the end of the second quarter on 2021. In the clinical trial, which is being performed in partnership with Quotient Sciences, Nanoform will investigate the behavior of an oral immediate release nanoformed formulation of piroxicam.
“The commencement of the first ever human trial of a drug nanoformed using our proprietary CESS technology is something we have been working tirelessly toward for many years, and we are very proud that our hard work has paid off in making the trial a reality ahead of schedule,” said Professor Edward Hæggström, Nanoform’s CEO, in the press release.
“Over the years, we have conducted hundreds of development programs on new drug candidates and we are incredibly pleased to be supporting Nanoform to validate their CESS technology,” added Mark Egerton, CEO of Quotient Sciences, in the press release. “We are committed to helping our customers bring new medicines to patients and eagerly await the outcome of the trial.”
Source: Nanoform
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.